Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
Researchers may have found the key to destroying the amyloid-β clumps long associated with Alzheimer's disease, which could spur new approaches to drug discovery in a field that has seen more than its share of failures.
An interesting development in this age of Irish-fueled tax inversion deals, the Mayo Clinic and Enterprise Ireland have begun a 5-year collaboration to advance med tech innovation.
Biotech Seres Health has raised a quick $10 million B round to support its work in microbiome R&D, appending a partnership with the Mayo Clinic as it advances an infectious disease treatment.
The blood-brain barrier is the body's way of keeping harmful substances away from the brain, but it's also a daunting obstacle for drug delivery experts looking to send treatments to the organ. Now, researchers at the Mayo Clinic have developed a synthetic peptide carrier to shuttle small molecules past the barrier and into the brain.
Sanovas, a devicemaker specializing in microinvasive surgery for the lungs, joined forces with the Mayo Clinic to market its outpatient treatment for asthma that relaxes the muscles that constrict the airways.
A technique known as metabolomics may enable an Alzheimer's disease blood test diagnosis before patients start displaying symptoms, Mayo Clinic scientists have concluded.
An experimental drug designed to block an overactive protein in kidney cancer may provide a more targeted approach to treating the common cancer and could eventually be used as a therapy for other types of the disease.
After scaling back its IPO price by about 85%, diagnostics outfit Cancer Genetics has some good news to report, pulling in $6.9 million once its under-writers exercised their over-allotment option.
With great fanfare, the Mayo Clinic won FDA approval late last year for a new diagnostic imaging agent that helps determine when prostate cancer has returned. But as Bloomberg reports, the non-profit medical center has struggled to expand access to the compound.